# Core A: Administrative Core

> **NIH NIH P01** · WEILL MEDICAL COLL OF CORNELL UNIV · 2021 · $198,152

## Abstract

Mantle cell lymphoma (MCL) is a non-Hodgkin's lymphoma that remains incurable due to the development of
drug resistance, which is typically marked by unrestrained tumor cell proliferation. Cell cycle dysregulation is a
hallmark of MCL. In particular, overexpression of CDK4, together with aberrant cyclin D1 expression, drives
unrestrained proliferation of tumor cells that underlies disease progression and expansion of resistant clones.
However, the molecular basis for drug resistance in MCL remains obscure. The overall goals of the program
project are: 1) to develop superior, mechanism-based combination therapies that both control tumor expansion
and enhance tumor killing in MCL, 2) to elucidate the mechanism(s) of drug resistance, and 3) to advance
genome-based patient and therapy stratification for optimal and durable clinical responses. To achieve these
goals, a team of investigators with strong, complementary expertise in basic science, cancer research,
experimental therapeutics and patient care at Weill Cornell Medicine (WCM) and The Ohio State University
OSU) have assembled three interactive projects to 1) target CDK4 in MCL therapy; 2) to elucidate the role of
FOXO and chromatin remodeling in cell cycle therapy for MCL; and 3) to target PRMT5 in MCL. These projects
are supported by four outstanding Cores: 1) Administrative Core, 2) Pathology Core; 3) Genomics and
Bioinformatics Core; and 4) Biostatistics Core. The projects and cores are highly integrated at both the
conceptual and technical levels, with ideas and unpublished data shared freely on a real-time basis. The PPG,
led by the Principal Investigator, will hold scheduled bi-weekly meetings via video conferencing in addition to
impromptu discussions, both face-to-face or via teleconferences and frequent phone calls and emails. The
chain of authority for decision-making and administration rests with the Principal Investigator, in consultation
with individual Project and Core leaders. The PPG is supported by an External Advisory Board composed of
four distinguished investigators who will participate in the annual review meeting in which progress and plans
for each Project and Core are presented for discussion and review. The PPG is further supported by Internal
Advisory Boards at WCM and OSU, who are available as needed for consultation, either singly or as a panel.
Synergy among Investigators, as well as between WCM and OSU, is the most outstanding feature of this PPG
and will propel its progress.

## Key facts

- **NIH application ID:** 10249090
- **Project number:** 5P01CA214274-04
- **Recipient organization:** WEILL MEDICAL COLL OF CORNELL UNIV
- **Principal Investigator:** SELINA Y CHEN-KIANG
- **Activity code:** P01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $198,152
- **Award type:** 5
- **Project period:** 2018-09-18 → 2023-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10249090

## Citation

> US National Institutes of Health, RePORTER application 10249090, Core A: Administrative Core (5P01CA214274-04). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10249090. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*